Skip to content
DataLookout
Menu

NCT07269470

Phase I/II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

StatusRecruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 5 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Phase changed: Phase 2 → Phase 1/2
    • Study title revised
  2. Notable Eligibility criteria expanded, about 6 words
  3. Notable Recruitment opened
    • Start date changed from estimate of Nov 1, 2026 to Jul 13, 2026
    • Site details revised
    v5
  4. Notable Start date: May 1, 2026 to Nov 1, 2026v4
  5. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety and Adverse Events (AEs)
Timeframe: Through study completion; an average of 1 year

Arms and interventions

Phase 2 Treatment with Dasatinib (PO) + Ropeginterferon (SC)Experimental

Participants will receive treatment on an outpatient basis.

Drugs: Dasatinib, Ropeginterferon alfa-2b (P1101)

Sites

1 site in 1 country

  • The University of Texas M. D. Anderson Cancer CenterHouston, Texas, United States